-
Metastatic Prostate Cancer Market Research 2025-2035, Featuring Key Players Such as AstraZeneca, Merck, BMS, Daiichi Sankyo, Telix, Exelixis, Eli Lilly and Co, Zenith Epigenetics, MacroGenics - ResearchAndMarkets.com
13 Jun 2025 14:42 GMT
… ; Co., Inc.
Bristol Myers Squibb
Daiichi Sankyo
Telix Pharmaceuticals
Exelixis
Eli Lilly … Portfolio
3.2.3 Top Competitors
3.2.4 Target Customers …
-
Global Antibody Drug Conjugates Market Report 2025-2035, Featuring F. Hoffmann La Roche, Daiichi Sankyo, Seagen, Gilead Sciences, Takeda, Pfizer, Astellas, AstraZeneca, ADC Therapeutics and Immunogen - ResearchAndMarkets.com
21 May 2025 12:40 GMT
… F. Hoffmann La Roche Ltd, Daiichi Sankyo Company, Limited Seagen Inc., Gilead …
F. Hoffmann-La Roche Ltd.
Daiichi Sankyo Company, Limited
Seagen Inc.
Gilead … .3.3 Customer Groups and Competitors
9.3.4 Analyst…
-
Fierce Pharma Asia—Daiichi ADCs' 1st-line nod, trial deaths; Takeda's TYK2 trial win
19 Dec 2025 18:29 GMT
… weekly news roundup of 2025, Daiichi Sankyo scored a key FDA approval … FDA has approved AstraZeneca and Daiichi Sankyo’s Enhertu in combination with … TYK2 inhibitor zasocitinib, a potential competitor to Bristol Myers Squibb’s …
-
Emrelis Could Establish AbbVie as a Competitor in MET-High NSCLC Treatment
29 Jul 2025 20:23 GMT
… increasing competition from companies like Daiichi Sankyo, Seagen, and ImmunoGen?
Neha Anand … oncology, setting it apart from competitors like Daiichi Sankyo, Seagen, and ImmunoGen, which … rising competition from companies like Daiichi Sankyo and ImmunoGen.
-
Ono’s TGCT therapy wins FDA approval, challenging Daiichi Sankyo
17 Feb 2025 18:19 GMT
… tumour (TGCT), introducing competition to Daiichi Sankyo’s Turalio (pexidartinib).
TGCT is … approval positions it as a competitor to Daiichi Sankyo’s Turalio, which became …
-
BTK Inhibitors Clinical Trial Pipeline Accelerates as 30+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight
17 Dec 2025 18:00 GMT
… , Roche, Shanghai Henlius Biotech, AbbVie, Daiichi Sankyo, Nuvation Bio, PDC*line Pharma … and actionable intelligence on their competitors and markets of interest to …
-
Daiichi Sankyo partners Alteogen on subcutaneous Enhertu
08 Nov 2024 15:10 GMT
Daiichi Sankyo has signed a deal worth … $280 million on offer from Daiichi Sankyo if the new formulation of … a major growth product for Daiichi Sankyo and AZ, with sales across … across HER2-positive solid tumours.
Competitors are in the offing, however …
-
Daiichi Sankyo eyes newer cancer drugs to stave off rivals
11 Oct 2024 10:37 GMT
Daiichi Sankyo will seek to maintain its edge over competitors in precision cancer therapies …
-
Daiichi Sankyo and Merck Enter into Global Development and Commercialization Agreement for MK-6070
07 Aug 2024 01:46 GMT
… Japan where Daiichi Sankyo will maintain exclusive rights. Daiichi Sankyo is solely … manufacturing and supply.
About Daiichi Sankyo
Daiichi Sankyo is an innovative global healthcare … products and patents attained by competitors; challenges inherent in new …
-
Daiichi Sankyo Company, Limited (DSKYF) Q1 2024 Earnings Call Transcript
05 Aug 2024 23:26 GMT
… pain treatment, Tarlige and Daiichi Sankyo healthcare product. In addition … gains of inventory for Daiichi Sankyo Espha products. So … preparations. AstraZeneca and Daiichi Sankyo are currently deepening discussions … 2, the data competitor in non-small cell …
About
© 1995-2025